Amgen works like a training ground to certain foreign individuals. Their own people who are already in hire them and since they are incapable they may be pushed out after some stay, but be able to use Amgen name to obtain a position in a smaller company. Many such examples exist. The industry penetration scheme.
Internal consultants at Lilly are not up to the task. They are often moved from the positions of responsibility to consultancy due to mediocre performance. Their advice is of low value. Could be interesting how this compares to similar internal consulting positions performance in other companies, like at Novo.
As many know and some experienced personally Amgen has a continuous improvement policy, but unfortunately it also involves personnel replacement. This is not necessarily "dead wood" cleaning, but a matter of policy. This brings mistrust, fear, uncertainty and volatility. Not to mention negative internal networking. Has additional effects like that some good people leave, and others avoid to join Amgen.
We watch in dismay how the company conducts acquisitions and collaborations. Throwing money into unworthy partners.
It tells there are no M&A skills in organization, no good know how in-house to evaluate technical and scientific value combined with some lack of local skills. Too many general managers, not enough technology managers. But hey, the markets are booming and competitors are even worse.
Future is in treating the obese, who bring the problem on themselves. No one needs such pharma and the high cost that is involved. The industry becomes unethical. This can be seen since it attracts unethical people from around the world who either occupy big American pharma companies, or start their own so called pharma shops. This could be only restricted by radical change of American Healthcare System. Not under the oligarchs. So the scum of the world, you are welcome.
Having many Advisors on board but the internal strategy lacks depth and sounds sometimes amateurish and half-baked. Opposite to what Novo is trying by inviting McKinsey and other heavy weights. Strategy is still old fashioned pharma preoccupied with daily grind.
No raises in sight in 2025, possibly layoffs. If any promotions, they will be as inflated titles. New layers of titles might be added. Salary reductions? Possibly not.
JMP red face, company could not provide a good estimate. Lilly under-utilizes and misuses talent they already have, and hires wrong people. How to compete with Novo? No good team work in international parts of the company and frictions among the domestic parts.
Gilead has a chance now to improve its position as well as re-evaluate approaches to cell therapy. Preferential treatment of
certain groups of employees must end.
